Barclays initiates Repligen at Overweight with $150 price target, optimistic about bioprocessing industry
From Barchart: 2025-06-24 16:36:00 Barclays has given Repligen Corporation (NASDAQ:RGEN) an Overweight rating and a $150 price target, praising its